Business Wire

OceanBase Records Over 100% Increase in Number of Customers

13.1.2022 09:59:00 EET | Business Wire | Press release

Share

OceanBase,an enterprise-level distributed relational database provider, announced during this year’s Distributed Database Developer Conference that its database products have been adopted by over 400 customers, which equals to a year-on-year increase of over 100% from 2020 to 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112006074/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Yang Bing, CEO of OceanBase, speaking during the Distributed Database Developer Conference on January 6, 2022. (Photo: Business Wire)

OceanBase, an Ant Group company, has seen its business expanding rapidly during the past year. So far, a quarter of the top 200 financial institutions in China have chosen OceanBase as a preferred technology provider to upgrade their core IT systems. OceanBase is also serving customers from non-financial service industries such as energy, telecommunication, and transportation. Customers from these sectors contribute to about 35 percent of OceanBase's total revenue.

Meanwhile, OceanBase is exploring the Small and Medium Enterprises (SMEs) market, which now accounts for near 70 percent of its customer base. Regional banks, insurers, security brokers, and wealth management companies have also been partnering with OceanBase and see it as one of the leading database technology providers.

"With its 'product-driven growth' business model, OceanBase aims to make database system management and operation easier and more seamless, " said Yang Bing, CEO of OceanBase. "We look forward to working with partners, customers, developers, and other industry participants to accelerate the development of database technology with continuous technology and product innovations."

"The distributed database is able to handle computing tasks across different nodes, bringing great advantages to dealing with large throughput and group computing," said Michael “Monty” Widenius, founder at MariaDB Foundation and the main author of the original version of the open-source MySQL in the conference. As for open-sourced database products like MariaDB and OceanBase, he commented, “Products and communities will maintain their vitality when they attract tens of millions of users while building healthy businesses."

The rapid development of the internet industry is accelerating the technology innovations of distributed databases that naturally have the ability to expand on a large scale. According to a recent report released by market intelligence provider Gartner, with advanced features including high availability, high scalability, multimodal implementation, supports of hybrid workloads and high compatibility, native distributed databases such as OceanBase are leading the trend of development in database technology, and the CAGR of the global market reaches 16.9 percent.

This year’s Distributed Database Developer Conference was co-hosted by CSDN, Mulan Open-source Community, Open Source China, and OceanBase on January 6. Other speakers participating in the conference included Bruce Momjian, co-founder and core team member of the PostgreSQL Global Development Group, Li Haixiang, the chief architect of Tencent's distributed database TDSQL, and Liu Song, VP of PingCAP.

About OceanBase

Launched in 2010, OceanBase is an enterprise-level distributed relational database developed by Ant Group. OceanBase’s benefits over alternative solutions include strong data consistency, high availability, high performance, low cost, online scalability, and high compatibility with SQL standards and other mainstream relational databases. Its performance has been proven in many Alipay large-scale business scenarios, as well as at the annual 11.11 Global Shopping Festival. In May 2020, OceanBase set the world record for online transaction processing performance, with 707 million transactions per minute in a TPC-C benchmark test. OceanBase was officially registered as a separate company in June 2020.

To learn more, please visit: https://www.oceanbase.com/en

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquires
Vick Li Wei
OceanBase
Vick.lw@antgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye